BeiGene, Ltd.
BGNE
Classificação em ações
#1179
BeiGene, Ltd. is a global biotechnology enterprise that operates across the... BeiGene, Ltd. is a global biotechnology enterprise that operates across the entire pharmaceutical value chain, encompassing the research, development, production, and worldwide commercialization of diverse therapeutic agents. The company's commercially available product lineup includes several important medicines: BRUKINSA, an agent used for relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab, prescribed for R/R classical Hodgkin's lymphoma; REVLIMID, indicated for multiple myeloma; VIDAZA, which addresses myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA, a treatment for giant cell tumor of bone; BLINCYTO, for acute lymphoblastic leukemia; KYPROLIS, another therapy for R/R multiple myeloma; SYLVANT, targeting idiopathic multicentric Castleman disease; QARZIBA, for neuroblastoma; Pamiparib, applicable to various solid tumors; and Pobevcy, indicated for metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). Within its robust clinical development pipeline, BeiGene is actively advancing numerous investigational compounds. Key candidates include Zanubrutinib, a BTK inhibitor designed to combat lymphomas; Tislelizumab, an anti-PD-1 antibody under investigation for a spectrum of solid and hematological cancers; Lifirafenib and BGB-3245, both in trials for melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor targeting NSCLC, melanoma, and other solid tumors. Further expanding its clinical assets are BGB-A333, a PD-L1 inhibitor for diverse solid tumors; Ociperlimab, a TIGIT inhibitor also aimed at various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor for mature B-cell malignancies; BGB-A445, an OX40 agonist antibody for solid tumors; Zanidatamab, a bispecific HER2 inhibitor addressing breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor for a range of solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene has also established strategic alliances with prominent industry partners, including Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. The company, incorporated in 2010, maintains its corporate headquarters in Cambridge, Massachusetts.
Preço da ação
$184.00
Última sincronização: 2025-01-02
Valor de mercado
$19.28B
Variação (1 dia)
-0.38%
Variação (1 ano)
0.00%
País
US
Negociar BeiGene, Ltd. (BGNE)
Categoria
Healthcare
Receita da BeiGene, Ltd. (BGNE)
Receita em Jun 2026 TTM: $6.13B
De acordo com os últimos relatórios financeiros da BeiGene, Ltd., a receita atual da empresa (TTM) é $6.13B. Em 2023, a empresa obteve uma receita de $2.46B um aumento em relação a a receita do ano 2022, que foi de $1.42B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da BeiGene, Ltd. de 2013 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $6.13B | 60.85% |
| 2024 | $3.81B | 54.96% |
| 2023 | $2.46B | 73.65% |
| 2022 | $1.42B | 20.37% |
| 2021 | $1.18B | 280.83% |
| 2020 | $308.87M | -27.87% |
| 2019 | $428.21M | 116.03% |
| 2018 | $198.22M | -16.85% |
| 2017 | $238.39M | 22,179.16% |
| 2016 | $1.07M | -87.86% |
| 2015 | $8.82M | -32.37% |
| 2014 | $13.04M | 16.93% |
| 2013 | $11.15M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 105.98% |
US
|
|
| $2.23B | -63.65% |
US
|
|
| $15.74B | 156.88% |
AU
|
|
| $6.02B | -1.76% |
NL
|
|
| - | - |
CH
|
